Hallman M, Merritt T A, Akino T, Bry K
Department of Pediatrics, University of Helsinki, Finland.
Am Rev Respir Dis. 1991 Dec;144(6):1376-84. doi: 10.1164/ajrccm/144.6.1376.
Although surfactant deficiency at birth is the major cause of respiratory distress syndrome (RDS), there is insufficient data on surfactant and surfactant inhibitors after birth. In the present study, a total of 345 airway specimens (AS) from 61 neonates of gestational age of 24 to 29 wk (54 with RDS) were analyzed for concentrations of phosphatidylcholine (PC), saturated PC (SPC), surfactant protein A (SP-A), nonsedimentable protein, and free amino acids in epithelial lining fluid (ELF). The relationship between surfactant indices, surface activity, and severity of RDS was studied. Treatment with human surfactant containing SP-A increased [PC]ELF and [SPC]ELF to levels found in infants without RDS. In placebo-treated infants similar concentrations were first reached between Days 4 and 7. Surfactant treatment increased the low SP-A/SPC ratio, although this ratio remained lower than that in exogenous surfactant. In RDS, the concentrations of free amino acids in ELF were 6 to 31 times higher than in infants without RDS. The nonsedimentable proteins of AS and cationic amino acids increased the minimum surface tension of SP-A-deficient surfactant from AS. Addition of SP-A improved the surface activity. According to multiple regression analysis, In [PC]ELF (p less than 0.0001), SPC/PC ratio (p less than 0.0001), In SP-A/SPC ratio (p less than 0.0002), and [protein]ELF (p less than 0.01) correlated with alveolar-arterial oxygen pressure gradient. Of the infants weighing less than 1,000 g, those who were going to die or develop bronchopulmonary dysplasia had a strikingly lower SP-A/SPC ratio during the first week (less than 25 ng/nmol) than those surviving without BPD.(ABSTRACT TRUNCATED AT 250 WORDS)
尽管出生时表面活性剂缺乏是呼吸窘迫综合征(RDS)的主要原因,但关于出生后表面活性剂和表面活性剂抑制剂的数据不足。在本研究中,对61例孕龄24至29周的新生儿(54例患有RDS)的345份气道标本(AS)进行了分析,以测定上皮衬液(ELF)中磷脂酰胆碱(PC)、饱和PC(SPC)、表面活性蛋白A(SP-A)、不可沉降蛋白和游离氨基酸的浓度。研究了表面活性剂指标、表面活性与RDS严重程度之间的关系。含SP-A的人表面活性剂治疗使[PC]ELF和[SPC]ELF升高至无RDS婴儿的水平。在安慰剂治疗的婴儿中,相似浓度在第4天至第7天首次达到。表面活性剂治疗增加了低SP-A/SPC比值,尽管该比值仍低于外源性表面活性剂中的比值。在RDS中,ELF中游离氨基酸的浓度比无RDS的婴儿高6至31倍。AS的不可沉降蛋白和阳离子氨基酸增加了AS中SP-A缺乏的表面活性剂的最小表面张力。添加SP-A可改善表面活性。根据多元回归分析,ln[PC]ELF(p<0.0001)、SPC/PC比值(p<0.0001)、ln SP-A/SPC比值(p<0.0002)和[蛋白]ELF(p<0.01)与肺泡-动脉氧分压梯度相关。体重小于1000 g的婴儿中,那些将死亡或发生支气管肺发育不良的婴儿在第一周的SP-A/SPC比值(低于25 ng/nmol)明显低于无支气管肺发育不良存活的婴儿。(摘要截短于250字)